In a translational study it has been demonstrated in a mouse model that oxaliplatin had a transient gonadotoxic effect on both gonads, while in a prospective evaluation of gonadal function in a small cohort of CRC patients treated with oxaliplatin-based protocols, reduced post-treatment AMH levels (a marker for ovarian reserve) and temporary amenorrhea were observed, though with a high rate of resumption of menses.27 This evidence concerns the gene AMH and colorectal carcinoma.